

Novel Therapeutic Targets for the Treatment of Cancer



Second Schulze Symposium

Friday, November 7, 2008 · 7:30 a.m. – 3:30 p.m.

Gonda Building, Rosemary Berkel Crisp, R.N. Lecture Hall, Room 19-101
Mayo Clinic, Rochester, Minn.

Speakers are from Mayo Clinic, unless otherwise indicated. Symposium will be recorded for future internal viewing.

7:30 – 8 a.m.

Continental Breakfast

8 – 8:10 a.m.

Welcome

Robert B. Diasio, M.D.

*William J. and Charles H. Mayo Professor
Director, Mayo Clinic Cancer Center*

Professor of Molecular Pharmacology and Experimental Therapeutics

MORNING SESSION - DNA Damage Induced Signaling as a Consequence and Target of Cancer Therapy

Larry M. Karnitz, Ph.D., Session Chair

Associate Professor of Pharmacology

Consultant, Division of Oncology Research, Department of Oncology

8:10 – 8:55 a.m.

Advances in Understanding of the S Phase Checkpoint

Larry M. Karnitz, Ph.D.

8:55 – 9:40 a.m.

Targeting Chk1 as a Strategy for Improving the Efficacy of Cancer Therapy

Gary K. Schwartz, M.D.

*Chief, Melanoma and Sarcoma Service, Department of Medicine
Memorial Sloan-Kettering Cancer Center, New York, N. Y.*

9:40 – 10:05 a.m.

The Role of MDC1 in Checkpoint Signaling

Zhenkun Lou, Ph.D.

Assistant Professor of Pharmacology

*Associate Consultant, Division of Oncology Research, Department
of Oncology*

10:05 – 10:20 a.m.

Break

10:20 – 11:05 a.m.

Secondary Mutation of BRCA1/2 as a Mechanism of Chemo- Resistance in BRCA1/2-Mutated Cancer

Toshiyasu Taniguchi, M.D., Ph.D.

*Assistant Member, Division of Human Biology and Public Health Sciences
Fred Hutchinson Cancer Research Center, Seattle, Wash.*

11:05 – 11:30 a.m.

2-Aminoflavone: A Novel DNA Damaging Agent Active in Breast Cancer Models

Matthew M. Ames, Ph.D.

Sandra J. Schulze Professor

*Chair, Department of Molecular Pharmacology and
Experimental Therapeutics*

11:30 – 11:55 a.m.

The Role of Topoisomerase I in Response to Selected DNA Crosslinking Agents

Scott H. Kaufmann, M.D., Ph.D.

Helen C. Levitt Professor

*Consultant, Division of Hematology, Department of Internal Medicine and
Division of Oncology Research, Department of Oncology*

11:55 a.m. – 1 p.m.

Lunch (by invitation)

Gonda Building, 19-105 Seminar Room

AFTERNOON SESSION - Proliferative Signaling and Its Inhibition in Cancer Therapy

Daniel D. Billadeau, Ph.D., Session Chair

Associate Professor of Immunology

*Consultant, Division of Oncology Research, Department of Oncology and
Department of Biochemistry and Molecular Biology*

1 – 1:45 p.m.

Ras: The Elephant in the Room for Cancer Treatment

Channing J. Der, Ph.D.

Professor, Department of Pharmacology

Lineberger Comprehensive Cancer Center

University of North Carolina, Chapel Hill, N.C.

1:45 – 2:30 p.m.

Protein Kinase C ι as an Oncogene and Potential Cancer Therapeutic Target

Alan P. Fields, Ph.D.

Professor of Pharmacology

*Director, Cancer Basic Science, Mayo Clinic Cancer Center, Jacksonville
Chair, Department of Cancer Biology, Mayo Clinic Cancer Center, Fla.*

2:30 – 3:15 p.m.

GSK3 β as a Novel Target of Cancer Therapy

Daniel D. Billadeau, Ph.D.

3:15 – 3:30 p.m.

Closing Remarks

Matthew M. Ames, Ph.D.

Scott H. Kaufmann, M.D., Ph.D.

*If questions, please contact symposium co-chairs,
Dr. Ames and Dr. Kaufmann, at 507.284.8950.*

Supported by The Richard M. Schulze Family Foundation